Ruti Immune closes a €1.6 million round to advance against COVID-19

Ruti Immune has recently attracted new capital. The Spanish company, a spin off from the biotechnology company Archivel Farma, has closed a financing round of $1.96 million (€1.6 million) through Capital Cell, in which more than 800 investors have participated, as confirmed by Luis Ruiz, CEO of the company. 

A large part of the investment, $736,000 (€600,000), has been contributed by Teodoro García, the majority shareholder of Archivel Farma and founder of the TGT group, one of the main companies in the cheese sector in Spain. The rest of the funds have been contributed by minority shareholders, according to Ruiz. With this operation, the company seeks to finance a multinational clinical trial for the efficacy of its coronavirus vaccine. In addition, the company also estimates to prepare the production capacity for possible global deployment in 2022. 

If you want to find more details about Ruti Immune and its latest financing round, download for free the Born2Invest mobile app. Our companion app brings you the latest business news in the world so you can stay informed.

The company’s initial objective was to explore whether the innate immunity caused by the Ruti Immune vaccine is effective in preventing Covid-19 infection or mitigating its effects

This type of immunity is the first line of response to unknown pathogens, is non-specific and does not generate antibodies.  Ruti Immune has administered the vaccine to eighty people in Argentine hospitals participating in the clinical trial Ruti Immune aims to become the first company in the world to register a broad-spectrum antiviral vaccine based on trained immunity, to be used as a first-line prophylactic agent against new or uncontrollable viral infections such as Sars-Cov-2, the causal agent of Covid-19. 

The company has already administered the vaccine to eighty people in Argentine hospitals participating in the clinical trial, which was approved during the last months of 2020 by Argentina’s National Administration of Drugs, Food and Medical Technology (Anmat). The vaccine will be administered to at least 300 workers in the various participating centers. Ruiz pointed out that nine hospitals in Argentina could host the clinical trial. With the vaccines already underway by Pfizer, BioNTech or Astrazeneca, the CEO of Ruti Immune is now focusing on what the company has described as “complimentary speech.” For the executive, the “advanced immunity strategy continues and the trials have to be approached in a different way once there are vaccines, we have to talk about the trained immunity,” he added. 

Ruti Immune is a spin off from Archivel Farma, a company based in Badalona (Barcelona) whose leading product, Ruti, is in advanced clinical development as a therapeutic vaccine for drug-resistant tuberculosis and bladder cancer. The tuberculosis vaccine developed by Archivel Farma has great advantages that make it one of the best candidates to develop a safe and fast vaccine. First of all, the advanced state of development of Ruti, a vaccine which has been developed since 2005 and in which more than twenty million euros have been invested, allows to ensure that the product does not have harmful effects, since there are many clinical trials which prove the safety of the vaccine. In addition, Archivel Farma already has the necessary facilities to manufacture two million annual doses of vaccine, and it would be easy to scale up the production capacities if necessary.

__

(Featured image by neelam279 via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.